Atrial Fibrillation Guidelines Updated

Published Online: Thursday, April 10, 2014
Follow Pharmacy_Times:
The American Heart Association, American College of Cardiology, and Heart Rhythm Society have updated their guidelines on management of atrial fibrillation. The new guidelines include recommendations regarding use of new oral anticoagulants—dabigatran, rivaroxaban, and apixaban—as well as warfarin. However, the guidelines do not specify preferences among the 3 new oral anticoagulants due to a lack of head-to-head trials and note that treatment decisions should be based on concerns including risk factors, cost, tolerability, patient preference, potential for drug interactions, and other clinical characteristics. The guidelines will be published in the Journal of the American College of Cardiology, Circulation, Journal of the American Heart Association, and Heart Rhythm.

To read more about the new guidelines on HCPLive, click here.
Related Articles
In a Phase 3 study, odanacatib significantly reduced the risk of osteoporotic fractures, but it also might have contributed to major cardiovascular events.
Approximately 6.5 million Americans are prescribed digoxin, a cardiac glycoside with a long, fascinating history.
Statin guidelines released jointly by the American Heart Association and the American College of Cardiology more accurately identify patients with heavy arterial plaque buildup for therapy.
Several new anticoagulants have entered the US market in recent years, but research to find reversal agents for these drugs is ongoing.
Latest Issues
$auto_registration$